StockData
Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc. (DYN) stock

DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$15.87−0.15 (-0.94%)

Close on Nov 18, 2026Market cap $2.96BP/E –Yield –

Dyne Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Dyne Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$480.43M. For fiscal 2025 it was -$405.13M. The highest annual figure on record is -$13.48M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$405.13M–
FY2024Dec 31, 2024-$294.75M–
FY2023Dec 31, 2023-$188.89M–
FY2022Dec 31, 2022-$156.71M–
FY2021Dec 31, 2021-$123.18M–
FY2020Dec 31, 2020-$47.67M–
FY2019Dec 31, 2019-$13.48M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$131.80M–
Q1 FY2026Mar 31, 2026-$145.14M–
Q4 FY2025Dec 31, 2025-$112.32M–
Q3 FY2025Sep 30, 2025-$91.17M–
Q2 FY2025Jun 30, 2025-$94.76M–
Q1 FY2025Mar 31, 2025-$106.87M–
Q4 FY2024Dec 31, 2024-$85.41M–
Q3 FY2024Sep 30, 2024-$74.88M–
Q2 FY2024Jun 30, 2024-$55.73M–
Q1 FY2024Mar 31, 2024-$78.73M–
Q4 FY2023Dec 31, 2023-$35.09M–
Q3 FY2023Sep 30, 2023-$50.77M–
Q2 FY2023Jun 30, 2023-$55.89M–
Q1 FY2023Mar 31, 2023-$47.14M–
Q4 FY2022Dec 31, 2022-$29.71M–
Q3 FY2022Sep 30, 2022-$43.69M–
Q2 FY2022Jun 30, 2022-$31.17M–
Q1 FY2022Mar 31, 2022-$52.14M–
Q4 FY2021Dec 31, 2021-$30.06M–
Q3 FY2021Sep 30, 2021-$27.83M–
Q2 FY2021Jun 30, 2021-$46.89M–
Q1 FY2021Mar 31, 2021-$18.40M–
Q4 FY2020Dec 31, 2020-$20.76M–
Q3 FY2020Sep 30, 2020-$12.04M–
Q2 FY2020Jun 30, 2020-$7.37M–
Q1 FY2020Mar 31, 2020-$7.50M–
Q4 FY2019Dec 31, 2019-$4.75M–

More Dyne Therapeutics figures

See a number that looks wrong?